SNSS, Sunesis Pharmaceuticals Inc.

** SNSS reported that the U.S. Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application, claiming certain compositions related to SNSS‘ Vosaroxin.

The patent will grant SNSS exclusive rights to certain Active Pharmaceutical Ingredient compositions of vosaroxin, as well as the final product related to such compositions, and provides patent exclusivity to mid 2030 in the United States. A family of corresponding patent applications are pending in the U.S. and internationally.

SNSS is currently enrolling patients with more than 110 active sites open in 14 countries in the VALOR trial, a Phase 3, multinational, randomized, double-blind, placebo-controlled, pivotal clinical trial of vosaroxin in combination with cytarabine in first relapsed or refractory acute myeloid leukemia.

Vosaroxin is a first-in-class anti-cancer quinolone derivative, (AQD), a class of compounds that has not been used previously for the treatment of cancer. Vosaroxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest and apoptosis.

SNSS is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers.

More about SNSS at www.sunesis.com.

****************

ADEP, Adept Technology Inc.

** ADEP reported that it has received a $1.4 million order for high-precision robots from a major international manufacturer of sophisticated automation equipment for use in the consumer electronics and information technology industries. The order is expected to be fulfilled and recognized as revenue over the next two quarters.

The company selected ADEP as its automation partner to provide advanced robotic systems to be integrated into their process equipment as part of a program by their end-user manufacturer for increasing production capacities.

The order for Adept Python(TM) linear modules will be used in high-throughput, high-precision material handling applications. Adept Python robots have proven over the years to deliver consistently reliable performance and yields for its end-user customers.

Additionally, the Adept SmartController CX controller and distributed controls platform allow the customer to fully leverage and benefit from ADEP’s inherent multi-robot support capabilities, allowing up to 15 individually-configured robots to be commanded through one controller.

ADEP’s Python linear modules were also selected for their industry-leading cleanliness in controlled environments, with available options that are capable of meeting Fed 209E class 1 cleanroom standards at high motion speeds.

ADEP is a global, leading provider of intelligent robots and autonomous mobile solutions and services that enable customers to achieve precision, speed, quality and productivity in their assembly, handling, packaging, testing, and logistical processes.

More about ADEP at www.adept.com.

****************

KORS, Michael Kors Holdings Ltd.

** On its third quarter fiscal 2012 results, KORS posted total revenue of $373.6 million, a 67.9% increase year over year, and gross profit of $221.9 million, a 75.1% increase compared to the same period the prior year.

For the fourth quarter fiscal 2012, KORS expects total revenue to be in the range of $350 million to $355 million and diluted earnings per share to be in the range of $0.10 to $0.12 for the quarter.

KORS is a world-renowned, award-winning designer of luxury accessories and ready to wear.

More about KORS at www.michaelkors.com.

********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.